5 Interactions found for:
Drug Interactions
No drug interactions were found for selected drugs: Eliquis, furosemide.
This does not necessarily mean no interactions exist. Always consult your healthcare provider.
Drug and Food Interactions
Moderate
Furosemide
+ Food
The following applies to the ingredients: Furosemide
Furosemide and ethanol may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and Pregnancy Interactions
Major
Furosemide
+ Pregnancy
The following applies to the ingredients: Furosemide
Professional Content
This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus; use is contraindicated according to some authorities.
AU TGA pregnancy category: C
US FDA pregnancy category: C
Comments: Use of this drug during pregnancy requires monitoring of electrolytes, hematocrit, and fetal growth.
Animal studies have revealed evidence of fetolethality. There are no controlled data in human pregnancy.
AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
References
- "Product Information. Lasix (furosemide)." sanofi-aventis PROD (2007):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Major
Eliquis
+ Pregnancy
The following applies to the ingredients: Apixaban (found in Eliquis)
Professional Content
Use is not recommended.
AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned.
Risk Summary: Insufficient data exists to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes.
Comments:
-Treatment can cause uterine bleeding, that may require gynecological surgical intervention.
-Treatment can cause placental hemorrhage and subsequent fetal loss.
-This drug may increase the risk of bleeding in the fetus and neonate.
-Females of reproductive potential that require anticoagulation should discuss pregnancy planning options with their healthcare provider.
Animal studies have failed to reveal evidence of adverse developmental effects. There are no controlled data in human pregnancy.
Use of this drug during labor or delivery in women receiving neuraxial anesthesia may result in epidural or spinal hematomas.
AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Canada Inc (2012):
Drug and Breastfeeding Interactions
Major
Furosemide
+ Breastfeeding
The following applies to the ingredients: Furosemide
Professional Content
Caution is recommended as use is contraindicated according to some authorities.
Excreted into human milk: Yes
Comments: The effects in the nursing infant are unknown.
References
- "Product Information. Lasix (furosemide)." sanofi-aventis PROD (2007):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Major
Eliquis
+ Breastfeeding
The following applies to the ingredients: Apixaban (found in Eliquis)
Professional Content
A decision should be made to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother.
Excreted into human milk: Unknown
Excreted into animal milk: Yes
The effects in the nursing infant are unknown.
Animal studies in lactation did not result in death of offspring. The drug was excreted in the milk of the animal model at a high milk to plasma ratio, possibly due to active transport.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Canada Inc (2012):
Therapeutic Duplication Warnings
No warnings were found for your selected drugs.Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Switch to: Professional Interactions
| Drug Interaction Classification | |
|---|---|
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication. |
|
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
| Unknown | No interaction information available. |
Disclaimer: This content should not be considered complete and should not be used in place of a call or visit to a healthcare professional. Use of this content is subject to our terms of use & medical disclaimer.